SCHEMBL2952191

SCHEMBL2952191

Cc1cc(Nc2c(C(N)=O)sc3c2ccc(=O)n3-c2ccsc2)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 4/20 0.40
CHRNA7 P36544 6/20 0.35
TDO2 P48775 1/20 0.32
PDE4B Q07343 1/20 0.31
BUB1 O43683 1/20 0.31
DHODH Q02127 1/20 0.31
BLM P54132 1/20 0.31
ALDH1A1 P00352 2/20 0.31
POLB P06746 1/20 0.31
HPGDS O60760 1/20 0.30
PRMT5 O14744 1/20 0.30
WDR77 Q9BQA1 1/20 0.30
NPC1 O15118 1/20 0.30
MAPT P10636 1/20 0.30
NFKB1 P19838 1/20 0.30
RAB9A P51151 1/20 0.30
NFKB2 Q00653 1/20 0.30
KMT2A Q03164 1/20 0.30
RELA Q04206 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2947103 0.89 DHODH (0.40) DHODHALDH1A1MAPTRAB9AKMT2A
SCHEMBL2958462 0.88 CSF1R (0.39) CSF1RCHRNA7TDO2PDE4BPOLB
SCHEMBL2952198 0.88 CSF1R (0.39) CSF1RCHRNA7TDO2DHODHMAPT
SCHEMBL2950317 0.88 CSF1R (0.39) CSF1RCHRNA7TDO2PDE4BDHODH
SCHEMBL2947364 0.83 CHRNA7 (0.40) CSF1RCHRNA7TDO2DHODHALDH1A1
SCHEMBL2956320 0.83 HPGD (0.34) CSF1RPDE4BALDH1A1NPC1MAPT
SCHEMBL2955910 0.81 CHRNA7 (0.44) CSF1RCHRNA7MAPT
Ammonia Solution, Strong SCHEMBL2958892 0.79 CHRNA7 (0.35) CSF1RCHRNA7TDO2DHODHPOLB
SCHEMBL1266478 0.79 CHRNA7 (0.35) CSF1RCHRNA7TDO2DHODHPOLB
SCHEMBL2956149 0.79 CSF1R (0.39) CSF1RCHRNA7TDO2PDE4BBUB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US claimed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US claimed
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK CSF1R 412/4885CHRNA7 1817/4885TDO2 502/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 CSF1R 328/4885CHRNA7 2079/4885TDO2 909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.